Loxo Oncology, Inc. Securities Litigation

If you purchased a significant amount of shares of Loxo Oncology, Inc. (NASDAQ: LOXO), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:Loxo Oncology, Inc.
Date Filed:January 24th, 2019
Sector:Health Care
Industry:Major Pharmaceuticals

According to the Complaint, Loxo is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers.

This action stems from a proposed transaction announced on January 7, 2019 (the "Proposed Transaction"), pursuant to which Loxo Oncology, Inc. ("Loxo" or the "Company") will be acquired by Eli Lilly and Company.

On January 5, 2019, Loxo's Board of Directors caused the Company to enter into an agreement and plan of merger (the "Merger Agreement") with Eli Lilly. On January 17, 2019, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction.

The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Loxo Oncology, Inc.

 
First Identified Complaint

Colleen Witmer, et al. v. Loxo Oncology, Inc., et al.

Date Filed:January 24th, 2019
Class Period Start:January 7th, 2019
Class Period End:January 24th, 2019
First Identified Complaint Filings
#Document TitleFiling Date